Cargando…

Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis

BACKGROUND AND AIMS: Anxiety and depression are prevalent in patients with inflammatory bowel diseases (IBD), especially during IBD flares. IBD therapies can profoundly affect the mood of patients with IBD. We aimed to determine the long-term impact of anti-tumor necrosis factor (anti-TNF) and immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebenhüner, Alexander R., Rossel, Jean-Benoît, Schreiner, Philipp, Butter, Matthias, Greuter, Thomas, Krupka, Niklas, Jordi, Sebastian B. U., Biedermann, Luc, Rogler, Gerhard, Misselwitz, Benjamin, von Känel, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411653/ https://www.ncbi.nlm.nih.gov/pubmed/34484421 http://dx.doi.org/10.1177/17562848211033763

Ejemplares similares

The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients
por: Jordi, Sebastian Bruno Ulrich, et al.
Publicado: (2022)

Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management
por: Ledergerber, Martina, et al.
Publicado: (2021)

Because I’m happy – positive affect and its predictive value for future disease activity in patients with inflammatory bowel diseases: a retrospective cohort study
por: Lang, Brian M., et al.
Publicado: (2023)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study
por: Lautenschlager, Severin A., et al.
Publicado: (2023)

Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients
por: Bianchi, Rahel, et al.
Publicado: (2022)

Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
por: Schüle, Solvey, et al.
Publicado: (2017)

The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients
por: Roth, René, et al.
Publicado: (2021)

Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn’s disease patients
por: Greuter, Thomas, et al.
Publicado: (2018)

Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Biedermann, Luc, et al.
Publicado: (2019)

Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients
por: Yoganathan, Priyatharsan, et al.
Publicado: (2021)

Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases
por: Fagagnini, Stefania, et al.
Publicado: (2017)

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines
por: Looser, Rahel, et al.
Publicado: (2023)

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
por: Bon, Lorenz, et al.
Publicado: (2019)

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study
por: Grob, Lorenz, et al.
Publicado: (2020)

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort
por: Hiller, Aimee, et al.
Publicado: (2019)

Genetic risk factors predict disease progression in Crohn’s disease patients of the Swiss inflammatory bowel disease cohort
por: Ditrich, Felicitas, et al.
Publicado: (2020)

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Roth, Nina, et al.
Publicado: (2019)

Eosinophilic esophagitis—established facts and new horizons
por: Biedermann, Luc, et al.
Publicado: (2021)

New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors
por: Zeitz, Jonas, et al.
Publicado: (2015)

Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis?
por: Schreiner, Philipp, et al.
Publicado: (2021)

Fistulizing Crohn’s Disease
por: Scharl, Michael, et al.
Publicado: (2017)

The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients
por: Yilmaz, Bahtiyar, et al.
Publicado: (2018)

Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease
por: Martinho-Grueber, Maude, et al.
Publicado: (2022)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis
por: Segna, Daniel, et al.
Publicado: (2021)

Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae
por: Villiger, Roxanne, et al.
Publicado: (2021)

Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
por: Spalinger, Marianne R., et al.
Publicado: (2016)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
por: Vögelin, Marius, et al.
Publicado: (2016)

Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021)

Anemia in Inflammatory Bowel Disease: An Under-Estimated Problem?
por: Rogler, Gerhard, et al.
Publicado: (2015)

Microbial Sensing by the Intestinal Epithelium in the Pathogenesis of Inflammatory Bowel Disease
por: Scharl, Michael, et al.
Publicado: (2010)

Inflammatory bowel disease in sub-Saharan Africa: a protocol of a prospective registry with a nested case–control study
por: Katsidzira, Leolin, et al.
Publicado: (2020)

Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
por: Stallhofer, Johannes, et al.
Publicado: (2023)

Patients’ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? – a patient survey
por: Barthel, Christiane, et al.
Publicado: (2015)

Myeloid differentiation primary response gene (MyD) 88 signalling is not essential for intestinal fibrosis development
por: Lutz, C., et al.
Publicado: (2017)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort
por: von Graffenried, Thea, et al.
Publicado: (2022)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pqhuadeuv6vdcisuhd09rm4al5